VAERS Update 10/21/22

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,447,520 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and Oct. 21, 2022, to the Vaccine Adverse Event Reporting System (VAERS).

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 31,696 reports of deaths and 263,462 serious injuries, including deaths, during the same time period.

There were a total of 5,435 reports of adverse events following the new COVID-19 bivalent booster as of Oct. 21, 2022. The data included a total of 45 deaths and 280 serious injuries. As of Oct. 27, 22.8 million people have received the updated bivalent booster dose.

Of the 31,696 reported deaths, 20,252 cases are attributed to Pfizer’s COVID-19 vaccine, 8,599 cases to Moderna, 2,752 cases to Johnson & Johnson (J&J) and no cases yet reported for Novavax.

Excluding “foreign reports” to VAERS, 887,564 adverse events, including 14,920 deaths and 92,482 serious injuries, were reported in the U.S. between Dec. 14, 2020, and Oct. 21, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 14,920 deaths reported as of Oct. 21, 7% occurred within 24 hours of vaccination and 15% occurred within 48 hours of vaccination.

In the U.S., 632 million COVID-19 vaccine doses had been administered as of Oct. 19, including 376 million doses of Pfizer, 238 million doses of Moderna and 19 million doses of J&J.

vaers data vaccine injury 102822

Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.

VAERS data from Dec. 14, 2020, to Oct. 21, 2022, for 6-month-olds to 5-year-olds show:

VAERS data from Dec. 14, 2020, to Oct. 21, 2022, for 5- to 11-year-olds show:

VAERS data from Dec. 14, 2020, to Oct. 21, 2022, for 12- to 17-year-olds show:

According to the CDC, “VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.”

  • 269 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death.
  • 1,336 reports of myocarditis and pericarditis with 1,167 cases attributed to Pfizer’s vaccine.
  • 301 reports of blood clotting disorders with 278 cases attributed to Pfizer.
  • 27 cases of postural orthostatic tachycardia syndrome (POTS) with all cases attributed to Pfizer’s vaccine.

VAERS data from Dec. 14, 2020, to Oct. 21, 2022, for all age groups combined, show:

Children’s Health Defense (CHD) asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following these three steps.

CDC pressured FDA to authorize COVID boosters without clinical trials

The CDC pressured U.S. regulators to clear COVID-19 boosters without clinical trial data, according to emails obtained by Judicial Watch.

CDC officials relayed to counterparts at the FDA in early August 2021 that they wanted authorization for Moderna and Pfizer boosters, as data began showing that the vaccines weren’t working as well as initially promoted.

The conversation took place on a call that was described by Dr. Phil Krause, a top FDA official, to several other FDA workers. On that call, the CDC “evidently stated” they would assemble all the data they were aware of on third dosing in the immunocompromised setting and send it to the FDA in hopes they would authorize a third dose for those with compromised immune systems under Emergency Use Authorization.

All COVID-19 vaccines were authorized only for emergency use at that time. No boosters had been authorized and no clinical data were available for a third vaccine dose. Less than two weeks later, the FDA authorized boosters for certain people, including immunocompromised persons.

The agency said “a thorough review of the available data” concluded the group “may benefit” from a third dose. The only data cited on efficacy were from two studies, one conducted by French researchers and another by Canadian researchers. Pfizer and Moderna hadn’t completed any clinical trials.

FDA slow-walked studies on COVID vaccine safety signals in elderly

The FDA took more than a year to follow up on a potential increase in serious adverse events in elderly people who received Pfizer’s COVID-19 vaccine, according to an investigative report published Tuesday by The BMJ.

According to The BMJ, in July 2021, the FDA “quietly disclosed” the findings of a potential increase in four types of serious adverse events in elderly people who had received a Pfizer COVID-19 vaccine: acute myocardial infarction, disseminated intravascular coagulationimmune thrombocytopenia, and pulmonary embolism.

The FDA disclosure lacked specific details, such as the magnitude of the increased potential risk, and the agency said it would “share further updates and information with the public as they become available.”

The FDA did not alert physicians or the public, via a press release or any other means, The BMJ investigator said.

Eighteen days later, the FDA published a study planning document that outlined a protocol for a follow-up epidemiological study for investigating the matter more thoroughly.

According to the BMJ, the recondite technical document disclosed the unadjusted risk ratio estimates originally found for the four serious adverse events, which ranged from 42% to 91% increased risk.

More than a year later, the status and results of the follow-up study are unknown. The BMJ report also alleged the FDA has not “publicly acknowledged other published observational studies or clinical trial reanalyses reporting compatible results.”

CDC knew COVID shots could cause myocarditis in young males months before telling the public 

Two months after COVID-19 vaccines were rolled out to the U.S. public, a statistically significant vaccine safety signal for myocarditis in males ages 8 to 21 appeared in the CDC’s VAERS database, but CDC officials waited another three months before alerting the public, according to a new study.

The study, “Delayed Vigilance: A Comment on Myocarditis in Association with the COVID-19 Injections,” by Karl Jablonowski, Ph.D., and Brian Hooker, Ph.D., P.E., was published on Oct. 17 in the International Journal of Vaccine Theory, Practice, and Research.

In their study, Jablonowski and Hooker recorded and analyzed the increasing incidence of myocarditis as it progressively became a statistically significant “signal” in VAERS.

In an interview with The Defender, Hooker said the paper shows a “strong, statistically significant vaccine adverse event ‘signal’ for myocarditis in males 8 to 21 years of age was seen on the VAERS database as early as Feb. 19, 2021, just two months after the release of the COVID-19 vaccine to the U.S. public.”

Yet, instead of sounding the alarm, “CDC officials buried the connection between COVID-19 vaccination and myocarditis until May 27, 2021,” Hooker added. “By this date, over 50% of the eligible U.S. population had received at least one mRNA COVID-19 vaccine.”

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,418,220 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and Sept. 16, 2022, to the Vaccine Adverse Event Reporting System (VAERS). That’s an increase of 10,811 adverse events over the previous week.

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 31,074 reports of deaths — an increase of 139 over the previous week — and 258,480 serious injuries, including deaths, during the same time period —  up 1,253 compared with the previous week.

There were a total of 563 reports of adverse events following the new bivalent booster COVID-19 vaccine as of Sept. 16, 2022. The data included a total of 5 deaths and 31 serious injuries.

Of the 31,074 reported deaths, 19,934 cases are attributed to Pfizer’s COVID-19 vaccine, 8,385 cases to Moderna, 2,704 cases to Johnson & Johnson (J&J) and no cases yet reported for Novavax.

Excluding “foreign reports” to VAERS, 868,175 adverse events, including 14,531 deaths and 90,422 serious injuries, were reported in the U.S. between Dec. 14, 2020, and Sept. 16, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 14,531 deaths reported as of Sept. 16, 7% occurred within 24 hours of vaccination and 15% occurred within 48 hours of vaccination.

In the U.S., 600 million COVID-19 vaccine doses had been administered as of Sept. 14, including 363 million doses of Pfizer, 231 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

vaers data vaccine injury september 23 2022Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.

VAERS data from Dec. 14, 2020, to Sept. 16, 2022, for 6-month-olds to 5-year-olds show:

VAERS data from Dec. 14, 2020, to Sept. 16, 2022, for 5- to 11-year-olds show:

VAERS data from Dec. 14, 2020, to Sept. 16, 2022, for 12- to 17-year-olds show:

  • 39,472 adverse events, including 4,277 rated as serious and 120 reported deaths.
    • According to the CDC, “VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.”
  • 269 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death.
  • 1,310 reports of myocarditis and pericarditis with 1,158 cases attributed to Pfizer’s vaccine.
  • 300 reports of blood clotting disorders with 277 cases attributed to Pfizer.
  • 26 cases of postural orthostatic tachycardia syndrome (POTS) with all cases attributed to Pfizer’s vaccine.

VAERS data from Dec. 14, 2020, to Sept. 16, 2022, for all age groups combined, show:

Children’s Health Defense (CHD) asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following these three steps.

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,379,438 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and Aug. 5, 2022, to the Vaccine Adverse Event Reporting System (VAERS). That’s an increase of 7,964 adverse events over the previous week.

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 30,162 reports of deaths — an increase of 181 over the previous week — and 251,075 serious injuries, including deaths, during the same time period — up 1,959 compared with the previous week.

Of the 30,162 reported deaths, 19,462 cases are attributed to Pfizer’s COVID-19 vaccine, 8,038 cases to Moderna, 2,613 cases to Johnson & Johnson (J&J) and no cases yet reported for Novavax.

Excluding “foreign reports” to VAERS, 854,084 adverse events, including 13,972 deaths and 87,488 serious injuries, were reported in the U.S. between Dec. 14, 2020, and Aug. 5, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 13,972 U.S. deaths reported as of Aug. 5, 7% occurred within 24 hours of vaccination, 15% occurred within 48 hours of vaccination and 54% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 604 million COVID-19 vaccine doses had been administered as of Aug. 3, including 357 million doses of Pfizer, 228 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

VAERS Update 7/1/22

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,329,135 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and July 1, 2022, to the Vaccine Adverse Event Reporting System (VAERS). That’s an increase of 14,541 adverse events over the previous week.

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 29,273 reports of deaths — an increase of 111 over the previous week — and 241,910 serious injuries, including deaths, during the same time period — up 684 compared with the previous week.

Of the 29,273 reported deaths, 18,937 cases are attributed to Pfizer’s COVID-19 vaccine, 7,724 cases to Moderna and 2,545 cases to Johnson & Johnson (J&J).

Excluding “foreign reports” to VAERS, 839,450 adverse events, including 13,547 deaths and 85,321 serious injuries, were reported in the U.S. between Dec. 14, 2020, and July 1, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 13,547 U.S. deaths reported as of July 1, 15% occurred within 24 hours of vaccination, 19% occurred within 48 hours of vaccination and 58% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 596 million COVID-19 vaccine doses had been administered as of June 29, including352 million doses of Pfizer, 225 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,301,356 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and June 10, 2022, to the Vaccine Adverse Event Reporting System (VAERS). That’s an increase of 6,027 adverse events over the previous week.

The data included a total of 28,859 reports of deaths — an increase of 327 over the previous week — and 238,412 serious injuries, including deaths, during the same time period — up 1,645 compared with the previous week.

Of the 28,859 reported deaths, 18,719 cases are attributed to Pfizer’s COVID-19 vaccine, 7,581 cases to Moderna and 2,493 cases to Johnson & Johnson (J&J).

Excluding “foreign reports” to VAERS, 831,801 adverse events, including 13,293 deaths and 84,151 serious injuries, were reported in the U.S. between Dec. 14, 2020, and June 10, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 13,293 U.S. deaths reported as of June 10, 16% occurred within 24 hours of vaccination, 20% occurred within 48 hours of vaccination and 59% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 590 million COVID-19 vaccine doses had been administered as of June 10, including349 million doses of Pfizer, 223 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.

U.S. VAERS data from Dec. 14, 2020, to June 10, 2022, for 6-month-olds to 5-year-olds show:

U.S. VAERS data from Dec. 14, 2020, to June 10, 2022, for 5- to 11-year-olds show:

  • 11,370 adverse events, including 294 rated as serious and 5 reported deaths.
  • 22 reports of myocarditis and pericarditis.
    The Defender has noticed over previous weeks that reports of myocarditis and pericarditis have been removed by the CDC from the VAERS system in this age group. No explanation was provided.
  • 44 reports of blood clotting disorders.

U.S. VAERS data from Dec. 14, 2020, to June 10, 2022, for 12- to 17-year-olds show:

U.S. VAERS data from Dec. 14, 2020, to June 10, 2022, for all age groups combined, show:

FDA authorizes Pfizer and Moderna COVID vaccines for younger children

Moderna and Pfizer-BioNTech’s COVID-19 vaccines are now authorized for emergency use in infants and young children as young as 6 months, CNN reported.

The FDA on Friday authorized Moderna’s vaccine for use in children 6 months through 17 years and the Pfizer-BioNTech vaccine for children 6 months through 4 years.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Wednesday unanimously voted 21-0 to recommend Pfizer and Moderna’s COVID-19 vaccines for infants and young children, stating the totality of the evidence available shows the benefits of the vaccines outweigh the risks of use.

The panel ignored pleas from experts, the vaccine-injured and a congressman representing 17 other lawmakers to halt authorization until questions about the safety and efficacy of COVID-19 vaccines for the nation’s youngest children could be properly addressed.

Pfizer’s three-dose vaccine would cover children 6 months to 5 years old, while Moderna’s two-dose vaccine covers children 6 months to 6 years old.

States have already ordered millions of doses made available prior to FDA authorization by the Biden administration.

White House officials said the administration of vaccines for these age groups could start as early as June 21.

CDC advisors hold impromptu meeting to get vaccines for kids rolled out by White House deadline

During a meeting Thursday, the CDC announced it scheduled a special two-day meeting of the Advisory Committee on Immunization Practices (ACIP) Friday to discuss authorization of Pfizer and Moderna’s COVID-19 vaccines for infants and young children.

The meeting to discuss authorization of Moderna’s COVID-19 vaccine for 6- to 17-year-olds is scheduled for June 22 and 23.

The CDC today discussed the safety, immunogenicity and efficacy of the Moderna shot in kids 6 months through 5 years of age and Pfizer’s vaccine in children 6 months through 4 years of age.

The ACIP is scheduled to vote Saturday.

“The entire process is set up to rubber-stamp the VRBPAC meetings from yesterday,” said Toby Rogers, Ph.D.

In a CHD.TV live blog, Dr. Liz Mumper, a pediatrician and Children’s Health Defense board member, said Pfizer showed an estimate of 80.3% vaccine efficacy but based it on only 7 cases in the placebo group and 3 in the vaccine group.

“These numbers are ridiculously small — the 80% may not stand” if more kids are included in the numbers, Mumper said.

Mumper also pointed out the shots being considered at today’s meeting were based on the original Wuhan strain that is no longer circulating.

“It is not so important how good a vaccine is at generating antibodies to Wuhan strain,” Mumper said. “[We] need long-term data about the impact of the shot on the number of kids who get COVID in [the] community and have severe or mild [cases].

Mumper said:

“U.S. VAERS data from Dec. 14, 2020, to June 3, 2022, for 6-month-olds to 5-year-olds show 1,658 adverse events, including 63 cases rated as serious and 3 reported deaths.

“The risk of a child dying if they have a diagnosis is 1,086/10,700,00 or 1086/10700000 = 0.00010149532. The risk of any child dying of COVID-19 over this time period is 1,086/73000000 = 0.00001487671.”

“Forty-nine states have already bought vaccines for children in the age groups being debated,” she added. “Seems like a done deal.”

FDA’s vaccine advisors endorse Moderna’s COVID vaccine for kids ages 6 to 17

The FDA’s vaccine advisory panel on Tuesday voted unanimously to recommend Moderna’s COVID-19 vaccine for children ages 6 to 17 after determining the benefits of the vaccine outweigh the risks for use.

VRBPAC voted 22 to 0 to recommend Moderna’s two-dose vaccine for 6- to 11-year-olds at half the strength of the adult version, and 22 to 0 in favor of authorizing the shot for 12- to 17-year-olds at the same strength as adults.

During the public comment session, individuals expressed concern over recommending a vaccine for an age group that has an almost zero risk of experiencing severe illness or death from COVID-19 and has already acquired a high level of natural immunity.

Dr. Tom Shimabukuro, a vaccine safety official at the CDC, said some data suggest a higher risk of myocarditis among people 18 to 39 years old after receiving Moderna’s COVID-19 vaccine, but findings were not consistent across various safety databases and were not statistically significant.

The CDC confirmed 635 cases of myocarditis, or heart inflammation, in the 5-to-17 age group out of almost 55 million doses of the Pfizer-BioNTech vaccine administered. The agency said the condition occurred most often in adolescent boys after receiving their second dose.

29-year-old’s career came ‘crashing’ down after Pfizer COVID vaccine injury

In an exclusive interview with The Defender, Hayley Lopez, 29, said she developed postural orthostatic tachycardia syndrome (POTS) after receiving her first dose of Pfizer’s COVID-19 vaccine and can no longer work.

Lopez said she didn’t want the vaccine, but under the Biden administration’s executive order, federal workers were required to get the vaccine or be fired.

Lopez, an air traffic controller at one of the U.S. Federal Aviation Administration’s busiest facilities in the country, said she experienced side effects within 15 minutes of receiving the shot.

She first noticed arm and chest pain, and within three days experienced dizziness, shortness of breath, memory issues and stuttering.

Lopez said her symptoms include twitching, nerve pain, fatigue, high blood pressure, high heart rate, palpitations, lightheadedness, a feeling of vertigo and migraines.

She had difficulty locating a doctor who could diagnose her condition and recognize her symptoms were vaccine-related.

Lopez got a diagnosis from a physician after reading about POTS — a condition that affects blood flow and can result in symptoms such as lightheadedness, fainting and increased heartbeat, symptoms which appear when standing up from a reclined position.

Florida only state not to preorder vaccines for young children

Florida is the only state in the nation that did not place an order with the federal government for doses of COVID-19 for young children prior to U.S. health agencies authorizing the vaccines, Politico reported.

The deadline for placing a pre-order was Tuesday and 49 other states met the cutoff date.

The Florida Department of Health (DOH), said in a statement to Politico on Wednesday that it did not pre-order vaccines for kids 5 and under because it doesn’t advise all children get vaccinated.

“States do not need to be involved in the convoluted vaccine distribution process, especially when the federal government has a track record of developing inconsistent and unsustainable COVID-19 policies,” the DOH statement said.

Jeremy Redfern, press secretary for Florida’s DOH, confirmed the department “chose not to participate” in the vaccination program.

“It is also no surprise we chose not to participate in distribution of the COVID-19 vaccine when the department does not recommend it for all children,” Redfern said. “Doctors can order vaccines if they are in need, and there are currently no orders in the department’s ordering system for the COVID-19 vaccine for this age group.”

Children’s Health Defense asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following these three steps.

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,255,355 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and April 29, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 27,758 reports of deaths — an increase of 226 over the previous week — and 226,703 serious injuries, including deaths, during the same time period — up 1,937 compared with the previous week. There were 8,224 additional total adverse events reported to VAERS over the previous week.

Excluding “foreign reports” to VAERS, 813,021 adverse events, including 12,779 deaths and 81,271 serious injuries, were reported in the U.S. between Dec. 14, 2020, and April 29, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 12,779 U.S. deaths reported as of April 29, 16% occurred within 24 hours of vaccination, 20% occurred within 48 hours of vaccination and 59% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 575 million COVID-19 vaccine doses had been administered as of April 29, including339 million doses of Pfizer, 217 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

VAERS Update 3/11/22

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,183,495 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and March 11, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 25,641 reports of deaths — an increase of 483 over the previous week — and 208,209 reports of serious injuries, including deaths, during the same time period — up 4,321 compared with the previous week.

Excluding “foreign reports” to VAERS, 788,624 adverse events, including 11,728 deaths and 76,231 serious injuries, were reported in the U.S. between Dec. 14, 2020, and March 11, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 11,728 U.S. deaths reported as of March 11, 17% occurred within 24 hours of vaccination, 22% occurred within 48 hours of vaccination and 60% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 556 million COVID vaccine doses had been administered as of March 11, including 328 million doses of Pfizer, 209 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,119,063 reports of adverse events following COVID vaccines were submitted between Dec. 14, 2020, and Feb. 11, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 23,990 reports of deaths — an increase of 375 over the previous week — and 192,517 reports of serious injuries, including deaths, during the same time period — up 4,382 compared with the previous week.

Excluding “foreign reports” to VAERS, 760,102 adverse events, including 10,909 deaths and 79,111 serious injuries, were reported in the U.S. between Dec. 14, 2020, and Feb. 11, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. 

Historically, VAERS has been shown to report only 1% of actual vaccine adverse events

U.S. VAERS data from Dec. 14, 2020, to March 11, 2022, for 5- to 11-year-olds show:

The most recent death involves a 7-year-old boy (VAERS I.D. 2152560) from Washington who died 13 days after receiving his first dose of Pfizer’s COVID vaccine when he went into shock and suffered cardiac arrest. He was unable to be resuscitated and died in the emergency department.

  • 17 reports of myocarditis and pericarditis (heart inflammation).

The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department.

U.S. VAERS data from Dec. 14, 2020, to March 11, 2022, for 12- to 17-year-olds show:

The most recent deaths involve a 17-year-old boy (VAERS I.D. 2171083) from Illinois with Duchenne muscular dystrophy who died from cardiac arrest after receiving his second dose of Pfizer’s COVID vaccine, and 14-year-old boy from Guam (VAERS I.D. 2157944) who died one week after his first dose of Pfizer when he suddenly committed suicide.

The boy’s VAERS report states: 

“Sudden suicide one week after the vaccine. Patient was a perfectly happy child. After the vaccine, he became much more tired and achy and lost interest in doing his sports. One week later, without any warning, he hung himself.”

  • 68 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to Pfizer’s vaccine.
  • 646 reports of myocarditis and pericarditis, with 634 cases attributed to Pfizer’s vaccine.
  • 162 reports of blood clotting disorders, with all cases attributed to Pfizer.

U.S. VAERS data from Dec. 14, 2020, to March 11, 2022, for all age groups combined, show:

Moderna on Thursday asked the FDA to amend Emergency Use Authorization (EUA) of its COVID vaccine to include a fourth dose for adults 18 and older. 

According to The Associated Press, the request is broader than Pfizer’s. Pfizer earlier this week asked the agency to authorize a fourth dose of its COVID vaccine for adults 65 and older. 

In a press release, Moderna said the request to include adults over 18 was made “to provide flexibility for the U.S. Centers for Disease Control and Prevention and healthcare providers to determine the appropriate use of an additional booster dose of mRNA-1273, including for those at higher risk of COVID-19 due to age or comorbidities.”

Moderna said its decision to seek FDA approval was based on studies from the U.S. and Israel about the Omicron variant, but didn’t provide further information. Booster doses of Moderna are half the dose of the first and second doses. 

Pfizer and BioNTech ask FDA to authorize fourth vaccine dose for older adults Pfizer and BioNTech on Tuesday said they submitted a request to the FDA for EUA of an additional booster dose of their COVID vaccine for adults 65 and older. 

The companies’ request was not based on robust, peer-reviewed U.S. data, but on two recent studies from Israel — both published on preprint servers without peer review.

The first study was done in conjunction with Israel’s Ministry of Health and involved a review of 1.1 million health records. The study concluded rates of COVID in those who received a fourth dose of Pfizer’s COVID vaccine were lower compared to those who received only three doses.

According to the preprint published on medRxiv, since Jan. 2 Israel has been administering a fourth dose of the Pfizer vaccine only to people over 60 and at-risk populations. 

In the second study of Israeli healthcare workers, results showed a fourth dose of either Pfizer’s or Moderna’s vaccine boosted antibody levels, but neither was effective at preventing infections.

CDC deletes thousands of reported COVID-19 deaths in children

The CDC removed tens of thousands of deaths linked to COVID, including nearly a quarter of deaths it had attributed to those younger than 18, The Epoch Times reported. The change was made on March 15 on its COVID data tracker website

“Data on deaths were adjusted after resolving a coding logic error. This resulted in decreased death counts across all demographic categories,” the CDC said on the website. The agency also acknowledged COVID death data is not complete. 

Before the change, the CDC listed 1,755 deaths in children from COVID, along with 851,000 others, according to Kelley Krohnert, a Georgia resident who tracks the CDC’s updates. 

The CDC removed 416 deaths among children and more than 71,000 other reported deaths — arriving at a total of about 780,000.

The CDC’s statistics are frequently cited by physicians and experts when pushing for children to receive COVID vaccines. Dr. Rochelle Walensky, the CDC’s director, referred to the tracker’s death total on November 2021 while pushing for an expert panel to advise her agency to recommend vaccination for all children 5 to 11 years old.

Vaccine researcher develops tinnitus 90 minutes after COVID shot, calls for more research

A vaccinologist at the Mayo Clinic in Minnesota said he developed tinnitus after receiving his second dose of an mRNA COVID vaccine.

Dr. Gregory Poland’s symptoms began 90 minutes after receiving the vaccine. He described the condition as “fairly severe” and “extraordinarily bothersome, interfering with sleep and the ability to concentrate.”

As of January 21, 2022 there have been 1,071,856 injuries including 22,607 deaths following COVID vaccination as reported to the U.S. government’s Vaccine Adverse Event Reporting System.

U.S. VAERS data from Dec. 14, 2020, to Dec. 3, 2021 for 5- to 11-year-olds show:
3,301 adverse events, including 58 rated as serious and 2 reported deaths. One death occurred in an 11-year-old girl from Georgia vaccinated Sept. 14, prior to the authorization of Pfizer’s COVID vaccine in the 5 to 11 age group.
The second death (VAERS I.D. 1890705) occurred in a 5-year-old girl who died four days after receiving her first dose of Pfizer.
U.S. VAERS data from Dec. 14, 2020, to Dec. 3, 2021 for 12- to 17-year-olds show:  
24,359 adverse events, including 1,474 rated as serious and 33 reported deaths.
The most recent deaths involve a 13-year-old girl from Texas (VAERS I.D. 1913198) who died 31 days after receiving her COVID vaccine. According to her VAERS report, the girl received her first dose of Pfizer on Aug. 1. Two weeks later, she complained of vague upper back pain and was diagnosed with a rare soft tissue cancer located on her heart despite having no previous medical history. Parents requested a VAERS report be filed in case her cancer was related to the vaccine. Her cancer and heart condition rapidly and progressively worsened and she died Dec 1.
The second death involves a 17-year-old girl from Minnesota (VAERS I.D. 1912785) who experienced cardiac arrest and died at home after receiving her first dose of Pfizer’s COVID vaccine.
60 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases
attributed to Pfizer’s vaccine.
567 reports of myocarditis and pericarditis (heart inflammation) with 557 cases attributed to Pfizer’s vaccine.
141 reports of blood clotting disorders, with all cases attributed to Pfizer.
U.S. VAERS data from Dec. 14, 2020, to Dec. 3, 2021, for all age groups combined, show:
19% of deaths were related to cardiac disorders.
54% of those who died were male, 42% were female and the remaining death reports did not include gender of the deceased.
The average age of death was 72.7.
As of Dec. 3, 4,538 pregnant women reported adverse events related to COVID vaccines, including 1,428 reports of miscarriage or premature birth.
Of the 3,249 cases of Bell’s Palsy reported, 51% were attributed to Pfizer vaccinations, 41% to Moderna and 8% to J&J.
784 reports of Guillain-Barré syndrome (GBS), with 42% of cases attributed to Pfizer, 29% to Moderna and 27% to J&J.
2,184 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
11,514 reports of blood clotting disorders. Of those, 5,112 reports were attributed to Pfizer, 4,101 reports to Moderna and 2,249 reports to J&J.
3,333 cases of myocarditis and pericarditis with 2,074 cases attributed to Pfizer, 1,109 cases to Moderna and 140 cases to J&J’s COVID vaccine.

This week’s U.S. VAERS data, from Dec. 14, 2020, to Nov. 5, 2021, for all age groups combined, show: